Author: Dominik Feldges, Dieter Bachmann
Source: Neue Zürcher Zeitung
Publication Date: December 19, 2025
Reading Time: approx. 5 minutes
Executive Summary
On December 19, 2025, Donald Trump announced a pharma deal with nine conglomerates—including Swiss giants Roche and Novartis—involving medication price cuts in exchange for three years of tariff exemption. While Trump celebrates the tariff threats as a negotiation victory, the actual impact on US healthcare costs remains unclear. New risks emerge for Switzerland: pharmaceutical companies could raise international prices to compensate for US discounts—with potential consequences for domestic supply.
Critical Guiding Questions
Freedom & Market Economics: How legitimate is state price dictation via tariff threats—and where are the boundaries between pragmatic regulation and economic extortion?
Transparency: Why don't the conglomerates publish detailed figures on expected profit losses? What is being withheld?
Accountability: Does Trump bear responsibility for potential price increases in other countries to finance US discounts?
Innovation: Does research into expensive niche areas face cuts when blockbuster medications are discounted?
Sovereignty: How can smaller countries like Switzerland protect their health policy if they are misused as "price buffers" for US policy?
Scenario Analysis: Future Perspectives
| Time Horizon | Expected Development |
|---|---|
| Short-term (1 year) | Roche/Novartis absorb US price pressure through international price increases; first rationing signals in Europe and CH; stock market stabilizes on hopes of limited impact |
| Medium-term (5 years) | Two-tier pharma market solidifies (US cheap, rest expensive); Switzerland risks market exit scenarios for specific medications; TrumpRx platform shows limited effect on overall price index |
| Long-term (10–20 years) | Pharmaceutical research concentrates on high-margin therapies (oncology, rare diseases); generic competition in USA grows; international regulation seeks counterweight to US hegemony |
Main Summary
Core Topic & Context
Trump has announced a political victory: nine pharmaceutical conglomerates—including Swiss flagships—lowered medication prices in exchange for three years of tariff freedom. This is Trump's second wave of deals (first in September with Pfizer, AstraZeneca). Background: US drug prices are two to three times higher than the OECD average; Trump pursues the "most-favored-nation" principle (lowest international prices as US standard).
Key Facts & Figures
- 14 of 17 contacted conglomerates have now completed deals (Abbvie, Regeneron still without agreement)
- Sample price cuts: Novartis' MS drug Mayzent drops from $9,987 to $1,137; Roche's flu medicine Xofluza from $168 to $50
- US medication spending (inflation-adjusted per capita): 1960: $100 → today: >$1,100
- Deadline open: Section-232 investigation (national security) ends January 9, 2026—sectoral tariffs could follow
- ⚠️ Overall effect unclear: No conglomerates published projections on overall price index impact
- Novo Nordisk forecast: 2026 growth hampered by "low single-digit percentage"
Stakeholders & Those Affected
| Winners | Losers | Uncertain |
|---|---|---|
| US patients (short-term) | Pharma R&D budget | International patients (CH, DE, etc.) |
| Trump (political capital) | Niche indications | Health insurers (as next target) |
| TrumpRx platform | Shareholders (partially) | Swiss regulators |
Opportunities & Risks
| Opportunities | Risks |
|---|---|
| Breakthrough in price regulation without legislative change | International price spiral upward |
| Precedent for other countries | Market exits from smaller markets |
| Billion-dollar investments in USA (Roche, Novartis) | Two-tier pharma market solidifies |
| Transparency via TrumpRx platform | Tariff risk remains (Section-232 until 1/9/2026) |
| Switzerland misused as "price buffer" |
Action Relevance for Decision-Makers
- Swiss regulators: Proactively negotiate with Roche/Novartis; secure supply guarantees to avoid price compensation
- Pharmaceutical industry: Monitor reputational risk; increase transparency on profit deterioration (currently too vague)
- Investors: Don't underestimate medium-term margin risks; Novo Nordisk and Eli Lilly transparent but conservative
- Supreme Court decision (by 1/2026): Could transform tariff strategy—Section-232 investigation still ongoing
Quality Assurance & Fact-Checking
- [x] Central statements (deal figures, price examples) verified from original source
- [x] Unconfirmed figures (overall price reduction effect) marked with ⚠️
- [x] Dates consistent (publication 19.12.2025, Section-232 deadline 9.1.2026)
- [x] Bias identified: NZZ article neutral-critical; no apparent political bias, but focus on Swiss perspective
Supplementary Research
- Peterson-KFF (market research): Confirms US price overcharge by factor 2–3 compared to other industrialized nations
- Section-232 investigation (pharma): Initiated April 14, 2025; decision expected January 9, 2026 or later
- Supreme Court: Deliberating tariff constitutionality; ruling expected 2025/2026—could overturn entire strategy
Source Directory
Primary Source:
Trump closes deal with Roche and Novartis – Neue Zürcher Zeitung, December 19, 2025
https://www.nzz.ch/wirtschaft/deal-um-deal-zu-tieferen-medikamentenpreisen-wie-trump-den-pharmafirmen-zugestaendnisse-abringt-ld.1917262
Supplementary Sources:
- Peterson-KFF Health System Tracker: International Drug Price Comparisons (confirms 2–3x price differences)
- US Department of Commerce – Section 232 Investigation (pharma industry, initiated 4/14/2025)
- NZZ Follow-up: It's too early for doom and gloom (12/18/2025) – Swiss pharmaceutical industry perspective
Verification Status: ✓ Facts checked December 19, 2025
This text was created with the support of Claude 3.5 Sonnet.
Editorial responsibility: clarus.news | Fact-checking: December 19, 2025